杭州生物医药产业再添新动能

Core Insights - In 2025, Hangzhou is set to have five Class 1 new drugs approved, accounting for 83% of the total in the province, marking a historical high and showcasing the city's strength in biopharmaceutical innovation [1] - The establishment of the Hangzhou Biopharmaceutical and Medical Device Industry Alliance aims to enhance resource circulation and address challenges such as fragmented innovation resources and insufficient collaboration within the industry [1][2] Group 1 - The alliance comprises 249 member units from various sectors, including government, industry, academia, research, healthcare, and finance, creating a comprehensive innovation community [2] - The alliance will implement three main mechanisms: quarterly activities, resource sharing, and demand response to empower member units effectively [2] - The first rotating chairman of the alliance, Ding Lieming from Betta Pharmaceuticals, emphasized the importance of the alliance in building a platform for resource sharing and collaborative innovation among biopharmaceutical companies [2] Group 2 - The alliance will focus on cutting-edge fields such as synthetic biology, nucleic acid drugs, and AI in pharmaceuticals, promoting deep integration of innovation chains, industry chains, capital chains, and talent chains [3] - The alliance will also serve as a high-end think tank, leveraging the expertise of its members to provide scientific support for the planning and decision-making of the biopharmaceutical industry cluster in Hangzhou [2]